Na Tang

1.6k citations
52 papers · 1.0k indexed · 1 hit paper · h-index 17
Topics
Cytomegalovirus and herpesvirus research (10 papers)CAR-T cell therapy research (6 papers)Virus-based gene therapy research (5 papers)

In The Last Decade

Na Tang

51 papers receiving 1.0k citations

Hit Papers

TGF-β inhibition via CRISPR promotes the long-term effica...2020202620222024202050100150200250

Peers

Na Tang
Comparison fields: 5 of 95
  • Oncology 510
  • Molecular Biology 456
  • Immunology 271
  • Genetics 143
  • Biomedical Engineering 142
Replace Kaushal Parikh with:
Kaushal Parikh Netherlands
Lei Dai China
Dae‐Seog Lim South Korea
Audrey Lasry Israel
Jackie E. Bader United States
Kary A. Latham United States
Cheolhee Won South Korea
Chunxiao Li China
Jürgen Brück Germany
Xun Sun China
Na Tang relative to Kaushal Parikh Netherlands Kaushal Parikh's profile →
Citations per field
00.5×2.6×
Kaushal Parikh · 1×
Citations per year

Countries citing papers authored by Na Tang

Since Specialization
Citations

This map shows the geographic impact of Na Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Na Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Na Tang more than expected).

Fields of papers citing papers by Na Tang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Na Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Na Tang. The network helps show where Na Tang may publish in the future.

Co-authorship network of co-authors of Na Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Na Tang. A scholar is included among the top collaborators of Na Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Na Tang. Na Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 11
4 7
5 2
6 1
7 5
8 8
9 99
10 65
11
TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumorsbreakdown →
293
12 14
13 6
14 29
15 9
16 44
17 24
18 42
19 19
20 28

About Na Tang

Na Tang is a scholar working on Oncology, Rheumatology and Epidemiology, having authored 52 papers that have together received 1.0k indexed citations. Recurring topics across this work include Cytomegalovirus and herpesvirus research (10 papers), CAR-T cell therapy research (6 papers) and Virus-based gene therapy research (5 papers). The work is most often cited by research in Oncology (510 citations), Immunology (271 citations) and Biological Psychiatry (19 citations). Na Tang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Haoyi Wang, Xiaofei Wei, Weidong Han, Xingying Zhang, Miaomiao Qiao, Na Li, Chen Cheng, Wei Mu, Chen Cheng and Hua Zhong. Their work appears in journals such as Nature Communications, The Journal of Immunology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026